TriangleNemtabrutinib (NCT04728893)
Nemtabrutinib trial for Hematologic Malignancies (NCT04728893). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with previously treated CLL/SLL, Richter transformation, mantle-cell, marginal-zone or follicular lymphoma, or Waldenström macroglobulinemia. Prior-treatment requirements differ by cohort; some require failure of both BTK and BCL-2 inhibitors.
The idea: take nemtabrutinib tablets once daily. It reversibly blocks BTK, disrupting survival signals in cancerous B cells, including cells with a C481S resistance mutation. Dose confirmation is followed by disease-specific expansion. Researchers measure response and side effects.
This phase 2 study plans 490 patients. Merck sponsors it; seven US locations list recruitment.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.